Apply to trial NCT07018037

A few quick questions so the study team can decide if you might be a fit.

Recruiting

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening